{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:44Z","timestamp":1782100184081,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Viatris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00546-w","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:02Z","timestamp":1776413102000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu in Asian Patients with Allergic Rhinitis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1995-4798","authenticated-orcid":false,"given":"Pongsakorn","family":"Tantilipikorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yau Kay Chung","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Huei","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yap Yoke","family":"Yeow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Kuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc Tung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Kumar","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"2","key":"546_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/ACI.0000000000000814","volume":"22","author":"DL Pham","year":"2022","unstructured":"Pham DL, Trinh THK, Le KM, et al. Characteristics of allergen profile, sensitization patterns and allergic rhinitis in SouthEast Asia. Curr Opin Allergy Clin Immunol. 2022;22(2):137\u201342.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"546_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4168\/aair.2018.10.4.370","volume":"10","author":"K Kulthanan","year":"2018","unstructured":"Kulthanan K, Chusakul S, Recto MT, et al. Economic burden of the inadequate management of allergic rhinitis and urticaria in Asian countries based on the GA(2)LEN model. Allergy Asthma Immunol Res. 2018;10(4):370\u20138.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"546_CR3","first-page":"143","volume":"33","author":"SY An","year":"2015","unstructured":"An SY, Choi HG, Kim SW, et al. Analysis of various risk factors predisposing subjects to allergic rhinitis. Asian Pac J Allergy Immunol. 2015;33(2):143\u201351.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"2","key":"546_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5415\/apallergy.2012.2.2.129","volume":"2","author":"JM Abong","year":"2012","unstructured":"Abong JM, Kwong SL, Alava HD, et al. Prevalence of allergic rhinitis in Filipino adults based on the National Nutrition and Health Survey 2008. Asia Pac Allergy. 2012;2(2):129\u201335.","journal-title":"Asia Pac Allergy"},{"issue":"3","key":"546_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.23822\/EurAnnACI.1764-1489.119","volume":"52","author":"S Norhafizah","year":"2020","unstructured":"Norhafizah S, Salina H, Goh BS. Prevalence of allergic rhinitis in children with otitis media with effusion. Eur Ann Allergy Clin Immunol. 2020;52(3):121\u201330.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"10","key":"546_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ppul.22554","volume":"47","author":"WC Chiang","year":"2012","unstructured":"Chiang WC, Chen YM, Tan HK, et al. Allergic rhinitis and non-allergic rhinitis in children in the tropics: prevalence and risk associations. Pediatr Pulmonol. 2012;47(10):1026\u201333.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"546_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40413-018-0198-z","volume":"11","author":"SN Chong","year":"2018","unstructured":"Chong SN, Chew FT. Epidemiology of allergic rhinitis and associated risk factors in Asia. World Allergy Organ J. 2018;11(1):17.","journal-title":"World Allergy Organ J"},{"issue":"8","key":"546_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70248","volume":"13","author":"Z Kanannejad","year":"2025","unstructured":"Kanannejad Z, Taylor WR, Mohkam M, et al. Urban lifestyle and climate-driven environmental exposures: immunological consequences for pediatric respiratory allergies. Immunity Inflamm Dis. 2025;13(8):e70248.","journal-title":"Immunity Inflamm Dis"},{"key":"546_CR9","doi-asserted-by":"crossref","unstructured":"Zheng M, Wang X, Latiff AHA, et al. An online survey of clinical practice for allergic rhinitis among the Asia-Pacific representatives. Asian Pac J Allergy Immunol. 2025;43:76\u201383.","DOI":"10.12932\/AP-310322-1361"},{"issue":"4","key":"546_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000351404","volume":"161","author":"E Meltzer","year":"2013","unstructured":"Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161(4):369\u201377.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"546_CR11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaci.2012.01.077","volume":"129","author":"W Carr","year":"2012","unstructured":"Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289.e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"546_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2500\/aap.2012.33.3587","volume":"33","author":"EO Meltzer","year":"2012","unstructured":"Meltzer EO, Laforce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324\u201332.","journal-title":"Allergy Asthma Proc"},{"key":"546_CR13","unstructured":"Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495\u2013503."},{"issue":"2","key":"546_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaip.2013.09.019","volume":"2","author":"WE Berger","year":"2014","unstructured":"Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2(2):179\u201385.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"546_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/pai.12540","volume":"27","author":"W Berger","year":"2016","unstructured":"Berger W, Meltzer EO, Amar N, et al. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment. Pediatr Allergy Immunol. 2016;27(2):126\u201333.","journal-title":"Pediatr Allergy Immunol"},{"key":"546_CR16","unstructured":"U.S Food and Drug Administration. Real-world evidence: considerations regarding non-interventional studies for drug and biological products 2024 [cited 2025 26\/06\/2025]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-evidence-considerations-regarding-non-interventional-studies-drug-and-biological-products. Accessed on 4 Aug 2024."},{"issue":"2","key":"546_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.anai.2010.06.008","volume":"105","author":"FC Hampel","year":"2010","unstructured":"Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168\u201373.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"546_CR18","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jaip.2018.01.031","volume":"6","author":"J Bousquet","year":"2018","unstructured":"Bousquet J, Meltzer EO, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732 e6.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"546_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2500\/aap.2016.37.3979","volume":"37","author":"L Klimek","year":"2016","unstructured":"Klimek L, Bachert C, Stjarne P, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: a pan-European study. Allergy Asthma Proc. 2016;37(5):376\u201386.","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"546_CR20","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00405-021-07048-1","volume":"279","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Xun Y, Shi X, et al. Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis. Eur Arch Otorhinolaryngol. 2022;279(5):2457\u201364.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"546_CR21","doi-asserted-by":"crossref","unstructured":"Sousa-Pinto B, Vieira RJ, Bognanni A, et al. Efficacy and safety of intranasal medications for allergic rhinitis: network meta-analysis. Allergy. 2024;80(1):94\u2013105.","DOI":"10.1111\/all.16384"},{"issue":"1","key":"546_CR22","doi-asserted-by":"publisher","first-page":"70.e3","DOI":"10.1016\/j.jaci.2019.06.049","volume":"145","author":"J Bousquet","year":"2020","unstructured":"Bousquet J, Sch\u00fcnemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70.e3-80.e3.","journal-title":"J Allergy Clin Immunol"},{"key":"546_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13601-016-0137-4","volume":"6","author":"J Bousquet","year":"2016","unstructured":"Bousquet J, Hellings PW, Agache I, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47.","journal-title":"Clin Transl Allergy."},{"key":"546_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-015-0008-0","volume":"1","author":"M Egan","year":"2015","unstructured":"Egan M, Bunyavanich S. Allergic rhinitis: the \u201cghost diagnosis\u201d in patients with asthma. Asthma Res Pract. 2015;1:8.","journal-title":"Asthma Res Pract"},{"issue":"12","key":"546_CR25","first-page":"1426","volume":"22","author":"B Harrow","year":"2016","unstructured":"Harrow B, Sedaghat AR, Caldwell-Tarr A, et al. A comparison of health care resource utilization and costs for patients with allergic rhinitis on single-product or free-combination therapy of intranasal steroids and intranasal antihistamines. J Manag Care Spec Pharm. 2016;22(12):1426\u201336.","journal-title":"J Manag Care Spec Pharm"},{"key":"546_CR26","first-page":"1","volume":"14","author":"P Stjarne","year":"2023","unstructured":"Stjarne P, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu (Dymista((R))) in Swedish patients with persistent allergic rhinitis, assessed by the visual analogue scale. Pragmat Obs Res. 2023;14:1\u201311.","journal-title":"Pragmat Obs Res"},{"issue":"4","key":"546_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/iid3.237","volume":"6","author":"R Kaulsay","year":"2018","unstructured":"Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immunity Inflamm Dis. 2018;6(4):456\u201364.","journal-title":"Immunity Inflamm Dis"},{"key":"546_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00412-z","author":"K Marth","year":"2024","unstructured":"Marth K, Renner A, Langmayr G, et al. An observational study to determine the real-life effectiveness of MP-AzeFlu\u00ae in Austrian patients with persistent allergic rhinitis. Drugs Real World Outcomes. 2024. https:\/\/doi.org\/10.1007\/s40801-023-00412-z.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"546_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2500\/aap.2015.36.3823","volume":"36","author":"L Klimek","year":"2015","unstructured":"Klimek L, Bachert C, Mosges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a non-interventional study. Allergy Asthma Proc. 2015;36(1):40\u20137.","journal-title":"Allergy Asthma Proc"},{"key":"546_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2147\/JAA.S277734","volume":"13","author":"R Van Weissenbruch","year":"2020","unstructured":"Van Weissenbruch R, Klimek L, G\u00e1lffy G, et al. MP-AzeFlu improves the quality-of-life of patients with allergic rhinitis. J Asthma Allergy. 2020;13:633\u201345.","journal-title":"J Asthma Allergy."},{"key":"546_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12948-020-00130-9","volume":"18","author":"D Price","year":"2020","unstructured":"Price D, Klimek L, Galffy G, et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clin Mol Allergy. 2020;18:15.","journal-title":"Clin Mol Allergy."},{"issue":"7","key":"546_CR32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1080\/03007995.2021.1911973","volume":"37","author":"GW Canonica","year":"2021","unstructured":"Canonica GW, Klimek L, Acaster S, et al. Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. Curr Med Res Opin. 2021;37(7):1259\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"546_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","volume":"47","author":"EF Juniper","year":"1994","unstructured":"Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81\u20137.","journal-title":"J Clin Epidemiol"},{"key":"546_CR34","doi-asserted-by":"crossref","unstructured":"Zhou B, Cheng L, Pan J, et al. Correction: a clinical study to assess the efficacy and safety of MP-AzeFlu nasal spray in comparison to commercially available azelastine hydrochloride and fluticasone propionate nasal sprays in Chinese volunteers with allergic rhinitis. Pulm Ther. 2023;9:411\u2013427.","DOI":"10.1007\/s41030-023-00238-8"},{"issue":"1","key":"546_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14656566.2018.1543401","volume":"20","author":"L Klimek","year":"2019","unstructured":"Klimek L, Sperl A, Becker S, et al. Current therapeutical strategies for allergic rhinitis. Expert Opin Pharmacother. 2019;20(1):83\u20139.","journal-title":"Expert Opin Pharmacother"},{"key":"546_CR36","first-page":"1","volume":"19","author":"J Agarwal","year":"2025","unstructured":"Agarwal J, Ramalingam RK, Kopietz F, et al. Introduction of MP-AzeFlu nasal spray for individuals with allergic rhinitis in Saudi Arabia and the United Arab Emirates: a budget impact analysis. Curr Med Res Opin. 2025;19:1\u201310.","journal-title":"Curr Med Res Opin"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00546-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:35Z","timestamp":1782098375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00546-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00546-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"5 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HCK, DTN, and RKR are employees of Viatris. All other authors declare no conflicts of interest associated with the publication of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data and materials are not publicly available. However, they can be provided upon reasonable request to the corresponding author. Any further inquiries should be directed to the corresponding author.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This is to declare that Pongsakorn, Julian, Yeh, Yeow, Chow, Kuhl and Nguyen and Rajesh contributed to constructing the concept and\u00a0design of the study, all the authors contributed to\u00a0data\u00a0acquisition and\u00a0interpretation, writing, editing and proofreading. All the authors have read and approved the final submitted manuscript and agreed to be accountable for the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The study was reviewed and approved by the institutional review boards (IRBs) of the participating sites. The Ethics Committee of Jawatankuasa Etika Penyelidikan Manusia, Universiti Sains Malaysia (JEPeM-USM) (No. USM\/JEPeM\/21110747) approved this study in Malaysia. The Central Research Ethics Committee (CREC; no. COA-CREC017\/2022) approved this study in Thailand. The research ethics committee of Hong Kong\u2019s Doctor\u2019s Union approved this study in Hong Kong. The Chang Gung Medical Foundation Institutional Review Board (IRB no.:202100254B0A3) approved the study in Taiwan.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The patients provided written informed consent\/pediatric assent. If the patient was minor, a parent or legal guardian must have provided written informed consent. The study followed all applicable laws and guidelines, the International Conference on Harmonization (ICH)\/Good Clinical Practices (GCP), in accordance with the principles of the Declaration of Helsinki and the US Code of Federal Regulations (CFR).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}